Valo Therapeutics, a developer of immunotherapy platforms, has acquired PeptiChip technology from the University of Helsinki.

The acquisition allows Valo to identify tumor antigens and develop new cancer immunotherapies.

Paul Higham, CEO of ValoTx, commented, “Precisely knowing the antigen profile of a tumor is crucial in developing new and effective immunotherapies in the treatment of cancer and particularly so when developing a personalized approach. PeptiCHIP enables us to identify these antigens faster than existing technologies and, in combination with our lead delivery platform, PeptiCRAd, we see significant potential for the development of personalized cancer immunotherapies across a wide range of cancers both for our partners and in-house programs.”